Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting

Presentation to highlight data from the CHABLIS-SC1, Phase 3 clinical study of blisibimod

Print
| Source: Anthera Pharmaceuticals, Inc.

HAYWARD, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present new data from the CHABLIS-SC1 Phase 3 clinical study of blisibimod, a novel treatment that targets B-cell activating factor (BAFF), at the American Society of Nephrology (ASN) Annual Meeting in New Orleans from October 31-November 5. This abstract focuses on the subgroup of subjects enrolled into the study with proteinuria equivalent to 0.5 g/day or higher. 

“This analysis of the CHABLIS-SC1 Phase 3 clinical study showed that treatment with blisibimod elicited clinically-meaningful decreases in urinary protein:creatinine ratio when administered for 1 year with concomitant standard-or-care medication to patients with systemic lupus erythematosus (SLE) with renal manifestations,” shared Kenneth Kalunian, MD, Professor of Medicine, Division of Rheumatology, Allergy and Immunology, University of California, San Diego.

Details of Anthera Pharmaceuticals’ ASN 2017 presentation is as follows:

Title: Effects of Blisibimod, A Selective Inhibitor of B-Cell Activating Factor, on Urinary Protein:Creatinine Ratio (UPCR) In Subjects With Renal Manifestations of Systemic Lupus Erythematosus (SLE)

Session:  1001-OR01 Immunology, Inflammation, and the Glomerulus: The Cutting Edge
Oral Abstract Session

When: November 2, 2017 from 6:06 PM to 6:18 PM

Location: Room 294 (Morial Convention Center)

Presentation Number: TH-OR069

All ASN abstracts are available on the conference website at https://www.asn-online.org

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on the Company can be found at www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.   Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT:

Investor Relations of Anthera Pharmaceuticals, Inc.
ir@anthera.com

For Media Inquiries:
Frannie Marmorstein, 305-567-0821
frannie.marmorstein@rbbcommunications.com

www.twitter.com/antherapharma
https://www.facebook.com/antherapharma/
https://www.linkedin.com/company/anthera-pharmaceuticals